Datum der Aufzeichnung: 20 May 2020

The last webinar in this four-part series elaborates on the value of nanoparticle tracking analysis (NTA) to the development of vaccines, including vaccine characterization of virus-like particles (VLPs) – such as those being developed as vaccines to COVID19.

More than a simple particle size analysis, the ability to rapidly make total (not just infective) particle concentration measurements is essential for vaccine developers looking to optimize the purity and shelf-life of their product. 

NTA allows you to visualize and size all particles in the preparation, generating important information about nano-particle content. Furthermore, NTA can delivers this data in a shorter time than TCID50 or plaque assays. For instance, the presence of larger particles could represent either non-viral cell debris from the cell culture process or aggregates of virus particles containing many individual virions. In either case, such aggregates/contaminants represent a possible problem to the manufacturer. In this you will see how the Malvern Panalytical NanoSight helps vaccine developers devise a solution.